AMDR, Consumer Group Clash Over Reprocessed SUD Risk
This article was originally published in The Gray Sheet
Executive Summary
The Center for Patient Advocacy's recent attempts to focus public attention on the safety risks of reprocessed single-use devices (SUDs) have drawn criticism from the Association of Medical Device Reprocessors
You may also be interested in...
Single-Use Device Reuse Needs Greater Federal Oversight - FDA, GAO
Manufacturers' inclusion of instructions for devices labeled for single-use on how to clean and reprocess the products would constitute a deceptive practice in the eyes of FDA, Center for Devices and Radiological Health Director David Feigal testified June 27.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.